前列腺素及E系列前列腺素受体4在前列腺化学性炎症大鼠模型膀胱过度活动发生中的作用
研究采用福尔马林诱导的大鼠非细菌性前列腺炎模型,检测膀胱黏膜和逼尿肌中前列腺素E2(PGE2)浓度及EP受体亚型表达,并评估膀胱内灌注选择性EP4拮抗剂ONO-AE3-208(30 μm)对膀胱活动的影响。结果显示炎症组膀胱黏膜和逼尿肌PGE2浓度及EP4蛋白水平显著升高,排尿间隔显著缩短,EP4拮抗剂可显著延长炎症组排尿间隔,而对对照组无显著影响。作者认为EP4激活与PGE2生成增加可能是前列腺炎症所致膀胱过度活动的重要促进因素。
要点
- 福尔马林诱导大鼠前列腺炎后,膀胱黏膜和逼尿肌PGE2浓度及EP4蛋白水平显著升高。
- 前列腺炎症大鼠排尿间隔较对照组显著缩短。
- 膀胱内灌注EP4拮抗剂ONO-AE3-208(30 μm)显著延长炎症组排尿间隔,对照组无显著变化。
核心结论
- 膀胱内灌注EP4拮抗剂有效改善前列腺炎症后的膀胱过度活动,EP4激活与膀胱黏膜PGE2生成增加似乎是前列腺炎症诱导膀胱过度活动的重要促进因素。
- 作者认为膀胱内阻断EP4可能成为伴有前列腺炎症的良性前列腺增生所致男性下尿路症状的治疗途径。
研究设计与样本
- 采用雄性Sprague-Dawley大鼠,双侧前列腺腹叶注射5%福尔马林(每叶50 μL)诱导非细菌性前列腺炎,对照注射溶媒。
- 诱导后10天取膀胱组织分离黏膜层和逼尿肌层,用ELISA和Western blotting分别检测PGE2浓度和EP1-4受体蛋白水平。
- 在对照组和福尔马林处理组进行清醒状态膀胱测压,并评估膀胱内灌注选择性EP4拮抗剂ONO-AE3-208(30 μm)对膀胱活动的影响。
主要发现
- 福尔马林注射组膀胱黏膜和逼尿肌层PGE2浓度及EP4蛋白水平较溶媒注射对照组显著升高,其他EP受体亚型无显著变化。
- 膀胱测压显示,前列腺炎症大鼠排尿间隔(ICIs)较对照组显著缩短。
- 膀胱内灌注ONO-AE3-208(30 μm)显著延长前列腺炎症大鼠的排尿间隔,而溶媒灌注无此效应。
- 同浓度ONO-AE3-208对对照组大鼠各项膀胱测压指标无显著影响。
临床怎么用
- 作者认为膀胱内阻断EP4可能成为伴有前列腺炎症的良性前列腺增生所致男性下尿路症状的治疗途径。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate, using a rat model of non-bacterial prostatic inflammation, the prostaglandin production and expression profiles of E-series prostaglandin (EP) receptor subtypes, which are reportedly implicated in the development of overactive bladder, in the bladder mucosa, and to investigate the effect of EP receptor type 4 (EP4) blockade on bladder overactivity after prostatic inflammation. METHODS: Male Sprague-Dawley rats were used. Prostatic inflammation was induced by formalin injection (5%; 50 μL per lobe) into the bilateral ventral lobes of the prostate. At 10 days after induction of prostatic inflammation or vehicle injection, bladder tissues from the deeply anaesthetized rats were harvested and separated into mucosal and detrusor layers. Then, prostaglandin E2 (PGE2) concentrations and protein levels of PGE2 receptors (EP1-4) in the bladder mucosa and detrusor were measured by ELISA and Western blotting, respectively. In separate groups of control and formalin-treated rats, awake cystometry was performed to evaluate the changes in bladder activity after prostatic inflammation. In addition, the effect of intravesical administration of a selective EP4 antagonist (ONO-AE3-208; 30 μm) on bladder activity was evaluated in control rats and rats with prostatic inflammation. RESULTS: PGE2 concentration and protein levels of EP4, but not other EP receptor subtypes, in the bladder mucosa and detrusor layers were significantly increased in formalin-injected rats vs vehicle-injected control rats. In cystometry, rats with prostatic inflammation exhibited a significant decrease in intercontraction intervals (ICIs) compared with control rats. Intravesical application of ONO-AE3-208 (30 μm), but not vehicle application, significantly increased ICIs in rats with prostatic inflammation, whereas ONO-AE3-208 at this concentration did not significantly affect any cystometric values in control rats. CONCLUSIONS: Because intravesical administration of an EP4 antagonist effectively improved bladder overactivity after prostatic inflammation, EP4 activation, along with increased PGE2 production in the bladder mucosa, seems to be an important contributing factor to bladder overactivity induced by prostatic inflammation. Thus, blockade of EP4 in the bladder could be a therapeutic approach to male lower urinary tract symptoms attributable to benign prostatic hyperplasia with prostatic inflammation.
引用
- Mizoguchi S, Wolf-Johnson AS, Ni J, et al. The role of prostaglandin and E series prostaglandin receptor type 4 receptors in the development of bladder overactivity in a rat model of chemically induced prostatic inflammation. BJU Int. 2019. PMID: 31166645. doi:10.1111/bju.14845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。